ALXO Q3 2025 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena

ALXOALX Oncology Holdings Inc.

$112M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$23M

Net Income

-$22M

EPS (Diluted)

$-0.41

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$83M

Total Liabilities

$38M

Stockholders' Equity

$45M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$23M	-$33M	+30.8%
Net Income	-$22M	-$31M	+27.9%